Eli Lilly (LLY) Stock Climbs 5% on Strong Q1 Results and Upgraded Forecast
Eli Lilly and Company, LLY Domestic sales expanded 43% to reach $12.1 billion. Markets outside the United States contributed $7.7 billion, up 81%, demonstrating the global appetite for GLP-1 therapies. Adjusted gross margin registered at 82.6%, declining modestly from the previous year as pricing dynamics on leading products created margin pressure. Chief Executive David Ricks highlighted the momentum. “We delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion,” he stated. Lilly increased its 2026 revenue forecast to $82.0–$85.0 billion from the earlier $80.0–$83.0 billion range. The midpoint of $83.5 billion exceeds Wall Streets consensus estimate of $81.67 billion. The company also elevated its adjusted EPS guidance to $35.50–$37.00, up from $33.50–$35.00 previously, with the revised midpoint of $36.25 beating the consensus of $34.53. Foundayo Launch Generates Mixed Signals The companys recently introduced oral GLP-1 medication Foundayo launched in early April, attracting significant attention as a competitive response to Novo Nordisk, which has established an early presence in the oral weight-loss medication category. Foundayo captured 3,707 prescriptions across the United States during the week that concluded April 17 — approximately half the ~8,000 prescriptions Wall Street anticipated. This underwhelming initial performance represents a potential concern for market observers. Ricks characterized the medication